Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lenvatinib plus pembrolizumab shows promising activity in NSCLC

Brose M et al. SITC 2018, Abstract P392

Key clinical point: Lenvatinib/pembrolizumab shows promise in metastatic NSCLC.

Major finding: Overall response rate at 24 weeks was 33.3%.

Study details: Interim findings in 21 patients from a phase 1b/2 study.

Disclosures: Dr. Brose has received consulting fees, research grants, and honorarium from Eisai.

Read the article here.

Citation:

Brose M et al. SITC 2018, Abstract P392

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Must Reads in Immuno-oncology

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514

Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9